Diplomat Pharmacy Inc (DPLO) : Cambridge Investment Research Advisors scooped up 475,961 additional shares in Diplomat Pharmacy Inc during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 524,872 shares of Diplomat Pharmacy Inc which is valued at $13,557,444.Diplomat Pharmacy Inc makes up approximately 0.32% of Cambridge Investment Research Advisors’s portfolio.
Other Hedge Funds, Including , Tower Research Capital (trc) boosted its stake in DPLO during the Q4 period, The investment management firm added 552 additional shares and now holds a total of 791 shares of Diplomat Pharmacy Inc which is valued at $20,432. Renaissance Group added DPLO to its portfolio by purchasing 9,578 company shares during the Fourth Quarter which is valued at $247,400. Diplomat Pharmacy Inc makes up approx 0.01% of Renaissance Group’s portfolio.Ftb Advisors boosted its stake in DPLO during the Q4 period, The investment management firm added 324 additional shares and now holds a total of 564 shares of Diplomat Pharmacy Inc which is valued at $14,568.Oppenheimerfunds boosted its stake in DPLO during the Q4 period, The investment management firm added 162,291 additional shares and now holds a total of 1,228,607 shares of Diplomat Pharmacy Inc which is valued at $31,734,919. Diplomat Pharmacy Inc makes up approx 0.04% of Oppenheimerfunds’s portfolio. Pathstone Family Office added DPLO to its portfolio by purchasing 575 company shares during the Fourth Quarter which is valued at $14,852. Diplomat Pharmacy Inc makes up approx 0.08% of Pathstone Family Office’s portfolio.
On the company’s financial health, Diplomat Pharmacy Inc reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Feb 29, 2016. Analyst had a consensus of $0.20. The company had revenue of $987.00 million for the quarter, compared to analysts expectations of $969.69 million. The company’s revenue was up 61.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS.
Many Wall Street Analysts have commented on Diplomat Pharmacy Inc. Diplomat Pharmacy Inc was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Diplomat Pharmacy Inc was Downgraded by JP Morgan to ” Neutral” on Mar 1, 2016. Mizuho Downgraded Diplomat Pharmacy Inc on Mar 1, 2016 to ” Neutral”, Price Target of the shares are set at $30.
Diplomat Pharmacy Inc opened for trading at $25.88 and hit $26.2 on the upside on Friday, eventually ending the session at $25.83, with a gain of 0.66% or 0.17 points. The heightened volatility saw the trading volume jump to 7,61,535 shares. Company has a market cap of $1,667 M.
Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.